Home Cart Sign in  
Chemical Structure| 302-79-4 Chemical Structure| 302-79-4

Structure of Retinoic acid
CAS No.: 302-79-4

Chemical Structure| 302-79-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Retinoic acid (Vitamin A acid) acts as an RAR nuclear receptor agonist and is used as an adjunct in cell therapy.

Synonyms: Vitamin A acid; all-trans-Retinoic acid; ATRA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Retinoic acid

CAS No. :302-79-4
Formula : C20H28O2
M.W : 300.44
SMILES Code : CC1(C(=C(CCC1)C)C=CC(=CC=CC(=CC(O)=O)C)C)C
Synonyms :
Vitamin A acid; all-trans-Retinoic acid; ATRA
MDL No. :MFCD00001551

Safety of Retinoic acid

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H315-H360-H410
Precautionary Statements:P201-P202-P264-P270-P273-P280-P301+P312+P330-P302+P352-P308+P313-P332+P313-P391-P405-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
femoral head chondrocytes 10 μM 3 days To investigate the effect of retinoic acid on aggrecan degradation in chondrocytes, results showed reduced aggrecan degradation products in Ndst1+/− samples upon RA treatment. PMC8422443
neurons 2 μM 1 week to induce neuronal differentiation PMC3170425
GABAergic neurons 1 μM 7 days to induce GABAergic neuron differentiation PMC3170425
Neuro-2a (N2A) cells 2 μM 5 days Induced differentiation of Hb9GFP mouse stem cells into motor neurons PMC5504286
mouse iPSCs 10 M not mentioned Differentiation of mouse iPSCs into neurospheres PMC10487333
iPSC-derived motoneurons 1 µM 4-10 days Used to induce differentiation of iPSCs into motoneurons, results showed that retinoic acid at 1 µM successfully induced motoneuron differentiation. PMC4338554
Human fetal lung capillary endothelial precursor cells 0.01, 0.1, 1 μM 24 hours To evaluate the effect of RA on endothelial cell proliferation, results showed RA increased cell proliferation in a concentration-dependent manner. PMC2715334

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Embryonic stem cells Culture medium 5 µM 7 days Induced differentiation of embryonic stem cells PMC8555894
Mice Osteoporosis model Gavage 70 mg/kg Once daily for 2 weeks Establish an osteoporosis model, results indicated the model was successfully established PMC6414964
Mice Osteoporosis model Gavage 70 mg/kg Once daily for 2 weeks To induce an osteoporosis model in mice by administering retinoic acid, the results showed that serum calcium and ALP levels in the model group were significantly increased, indicating the successful establishment of the osteoporosis model. PMC6414964
ICR mice UVB-induced skin damage model Oral and topical application 2 mg/kg Once daily for one week Retinoic acid as the positive control improved UVB-induced skin damage but did not significantly reduce oxidative stress and inflammation, and caused liver damage. PMC9504230

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05281965 Autism|Treatment Adherence|Ret... More >>inoic Acid|Dup15Q Syndrome Less << EARLY_PHASE1 UNKNOWN 2024-06-01 Zhejiang University, Hangzhou,... More >> Zhejiang, 310000, China|Miao pu, Hangzhou, 310009, China Less <<
NCT04417348 Melasma COMPLETED 2019-12-15 Dermatology Department. Hospit... More >>al Central "Dr. Ignacio Morones Prieto", San Luis Potosí, 78290, Mexico Less <<
NCT03999684 Adenoid Cystic Carcinoma PHASE2 COMPLETED 2020-04-15 Massachusetts General Hospital... More >> Cancer Center, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT01349556 Medication Reaction WITHDRAWN 2025-03-14 -
NCT02249767 Acne PHASE3 COMPLETED 2025-06-14 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.33mL

0.67mL

0.33mL

16.64mL

3.33mL

1.66mL

33.28mL

6.66mL

3.33mL

References

 

Historical Records

Categories